Cardiac Failure Review最新文献

{"title":"When the Heart Meets the Pillow: Building Cross-disciplinary Solutions for Sleep-disordered Breathing.","authors":"Madison Rosen, Lee R Goldberg","doi":"10.15420/cfr.2025.47","DOIUrl":"10.15420/cfr.2025.47","url":null,"abstract":"<p><p>The interplay between sleep-disordered breathing (SDB) and cardiovascular disease, particularly arrhythmias and heart failure, is complex and bidirectional. This article examines the impact of SDB in cardiovascular disease and heart failure. It is proposed that teams interested in improving SDB diagnosis and management take ACTION (assess for risk factors/screening in each visit; collaborate with sleep colleagues for referrals/visits; test for SDB with home sleep apnoea test, polysomnography; intervene with SDB-specific treatment (oral devices, continuous positive airway pressure, bilevel positive airway pressure, phrenic nerve and hypoglossal nerve stimulators) including risk factor modification (weight reduction, alcohol abstinence); continue ongoing assessment by cardiology and sleep teams for feedback about treatment; creating niche programmes for AF, heart failure and weight loss.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e23"},"PeriodicalIF":12.2,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the Benefits of the Comprehensive Disease-modifying Pharmacological Treatment in Patients with Heart Failure.","authors":"Carlos Escobar, Pedro Caravaca-Pérez, José Maria Fernandez-Rodriguez, Ines Gomez-Otero, Ainara Lozano-Bahamonde, Alejandro I Pérez-Cabeza, José Pérez-Silvestre, Carles Rafols, Jesús Saldaña-García, Alberto Esteban-Fernández","doi":"10.15420/cfr.2026.02","DOIUrl":"10.15420/cfr.2026.02","url":null,"abstract":"<p><p>To determine the effects of the comprehensive disease-modifying pharmacological approach among patients with heart failure with reduced ejection fraction, a cross-trial, aggregate-data analysis was performed to estimate the expected combined effect of quintuple therapy by multiplying trial-level HRs, assuming independent and multiplicative treatment effects from Phase III randomised clinical trials: EMPHASIS-HF, PARADIGM-HF, pooled DAPA-HF and EMPEROR-Reduced, and pooled VICTORIA and VICTOR. The imputed aggregate treatment effects on the primary endpoint of cardiovascular death or first heart failure hospitalisation were favourable to the quintuple compared with conventional therapy (HR 0.34; 95% CI [0.27-0.42]). This also occurred for cardiovascular death alone (HR 0.47; 95% CI [0.35-0.63]), first heart failure hospitalisation (HR 0.31; 95% CI [0.23-0.40]) and all-cause mortality (HR 0.51; 95% CI [0.39-0.67]). The numbers needed to treat per year for the primary outcome, cardiovascular death and first heart failure hospitalisation were 10, 23 and 15, respectively. Our findings support the potential benefit of comprehensive therapy, with the incremental role of vericiguat likely greatest in higher-risk patients or those with recent worsening heart failure.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e22"},"PeriodicalIF":12.2,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship of Cardiopulmonary Exercise Capacity to Coronary Microvascular Function and Body Composition in Patients with Suspected Heart Failure with Preserved Ejection Fraction.","authors":"So Ree Kim, Dong-Hyuk Cho, Mi-Na Kim, Jung-Joon Cha, Bo Ryun Kim, Jeong Hoon Yang, Seong-Mi Park","doi":"10.15420/cfr.2026.16","DOIUrl":"10.15420/cfr.2026.16","url":null,"abstract":"<p><strong>Background: </strong>Exercise intolerance in heart failure reflects heterogeneous mechanisms, including coronary microvascular dysfunction (CMD), obesity and sarcopenia. The aim of this study was to investigate the relationships between cardiopulmonary exercise capacity, coronary microvascular function and body composition in patients with suspected heart failure with preserved ejection fraction (HFpEF).</p><p><strong>Methods: </strong>In this single-centre cross-sectional study, consecutive patients presenting with chest discomfort or dyspnoea and an intermediate or high probability of HFpEF were enrolled. All patients underwent body composition analysis, adenosine stress echocardiography for coronary flow reserve (CFR) and cardiopulmonary exercise testing to assess peak oxygen consumption (VO₂ peak).</p><p><strong>Results: </strong>Of the 101 patients (mean age 63 years; 52.0% women), CMD (CFR <2.5) was present in 40.6%. Mean VO₂ peak was 23.0 ± 5.3 ml/min/kg. Patients with lower VO₂ peak (<23 ml/min/kg) had higher visceral fat area and percentage body fat. VO₂ peak correlated positively with CFR (r=0.344, p<0.001) and septal e' velocity and inversely with E/e'. Skeletal muscle mass index correlated positively with VO₂ peak predominantly in obese patients (BMI ≥25 kg/m²). In multivariable analysis, both CFR and degree of body fat remained independent correlates of VO₂ peak.</p><p><strong>Conclusion: </strong>In patients with suspected HFpEF, cardiopulmonary exercise capacity is closely associated with left ventricular diastolic function, coronary microvascular function and body composition. Preserved skeletal muscle mass may mitigate the adverse impact of obesity on exercise performance. These findings highlight the importance of integrated assessment of CMD and body composition and support targeted lifestyle and exercise interventions to improve functional capacity in HFpEF phenotypes.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e20"},"PeriodicalIF":12.2,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Diastolic Dysfunction and Postoperative Heart Failure in Non-cardiac Surgeries.","authors":"Sheizaf Gefen, Ofer Havakuk, Lior Zornitzki, Shir Frydman, Michal Laufer-Perl, Daniel Karlsberg, Yoav Granot","doi":"10.15420/cfr.2026.04","DOIUrl":"10.15420/cfr.2026.04","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular complications are a leading cause of morbidity and mortality following non-cardiac surgery. Although the association between systolic dysfunction and perioperative outcomes is well recognised, the prognostic significance of diastolic dysfunction remains underexplored and is not incorporated into risk models. This study investigated whether preoperative diastolic dysfunction is associated with adverse in-hospital outcomes following non-cardiac surgery.</p><p><strong>Methods: </strong>This retrospective cohort study included 3,882 adults who underwent non-cardiac surgery between 2011 and 2021 and had preoperative echocardiographic assessment of diastolic function. Diastolic dysfunction was graded per 2016 American Society of Echocardiography guidelines and categorised as normal/grade 1 (normal left-sided filling pressure [NLFP]) or grade 2/3 (elevated left-sided filling pressure [ELFP]). The primary outcome was a composite of in-hospital mortality and acute heart failure.</p><p><strong>Results: </strong>The primary outcome occurred in 22.3% of patients with ELFP and 11.6% of patients with NLFP (OR 2.1; 95% CI [1.7-2.6]; p<0.001). In-hospital mortality was 9.1% in the ELFP group and 4.2% in the NLFP group (OR 2.2; 95% CI [1.6-3.0]). Pulmonary oedema (3.8% versus 0.7%; OR 4.9; 95% CI [2.9-8.4]), furosemide use (12.9% versus 5.5%; OR 2.5; 95% CI [1.9-3.2]) and vasoactive medication administration (7.9% versus 5.4%; OR 1.5; 95% CI [1.1-2]) were more frequent in the ELFP group. These associations persisted after adjustment for echocardiographic and clinical parameters. Stratified analysis showed the association was strongest in intermediate- to high-risk surgeries.</p><p><strong>Conclusion: </strong>Diastolic dysfunction is independently associated with adverse postoperative outcomes in non-cardiac surgery. Incorporating diastolic parameters into preoperative risk assessment may improve perioperative outcomes.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e21"},"PeriodicalIF":12.2,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13573010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2025 American Academy of Sleep Medicine Central Sleep Apnoea Guidelines and the Heart Failure Patient.","authors":"Simon M Kaplan, Richard B Berry, William T Abraham","doi":"10.15420/cfr.2025.60","DOIUrl":"10.15420/cfr.2025.60","url":null,"abstract":"<p><p>Central sleep apnoea (CSA) and Cheyne-Stokes respiration are prevalent in patients with heart failure and contribute to disease progression, increased risk of death, heart failure hospitalisations and reduced quality of life. The 2025 American Academy of Sleep Medicine Clinical Practice Guideline for the Treatment of Central Sleep Apnea in Adults represents a major advance, recognising transvenous phrenic nerve stimulation as an evidence-based therapy for adults with CSA, including those with heart failure, as well as updating the clinical data on adaptive servo-ventilation. This review summarises key updates in the American Academy of Sleep Medicine 2025 guideline, examines the pathophysiological link between CSA and heart failure, and evaluates the clinical evidence and practical considerations for treatment. Current evidence indicates improvements in apnoea indices, oxygenation and quality of life, while the effect on mortality and hospitalisation needs additional prospective randomised data. Identification of patients with signs and symptoms which are likely due to central sleep apnoea is often missed in clinical practice, and treatment has a significant impact on quality of life.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e18"},"PeriodicalIF":12.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidimensional and Multidisciplinary Management of Heart Failure Patients with Frailty.","authors":"Cristiana Vitale, Gabriele Fragasso, Izabella Uchmanowicz, Angela Sciacqua, Pablo Díez-Villanueva, Shirley Sze, Quin E Denfeld, Markus S Anker, Elena Marques-Sule, Anna Strömberg, Emanuelle Berthelot, Stephan von Haehling, Giuseppe Rosano, Wolfram Doehner, Yuhui Zhang, Camilla Hage","doi":"10.15420/cfr.2025.48","DOIUrl":"10.15420/cfr.2025.48","url":null,"abstract":"<p><p>This paper discusses the considerations for multidimensional and multidisciplinary management of heart failure (HF) patients with frailty. Frailty is a multidimensional, dynamic and potentially reversible state, defined by clinical, functional, psycho-cognitive and social domains. Frailty is seldom systematically assessed in clinical practice in HF patients. Paradoxically, although the absolute benefit of HF guideline-directed medical treatment in frail HF patients seems greater, it is under-prescribed. This therapeutic gap could be related to different reasons, such as concerns about safety, polypharmacy and the lack of specific evidence-based data. Frail HF patients require a comprehensive, multidimensional therapeutic strategy that integrates available evidence-based pharmacological interventions with targeted non-pharmacological modalities across multiple clinical disciplines to optimise patient outcomes. The four domains of frailty should be objectively and routinely assessed with a multidimensional approach to facilitate a more individualised and comprehensive care plan delivered by a multidisciplinary team. In the future, we need more dedicated studies and randomised clinical trials that include frail HF patients.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e19"},"PeriodicalIF":12.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13458406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148713183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Function Abnormalities in Acute Heart Failure: A State-of-the-art Review from an International Expert Group.","authors":"Oliviana Geavlete, Andrew P Ambrosy, Alexandre Mebazaa, Sean P Collins, Jan Biegus, Marianna Adamo, John Teerlink, Giuseppe Mc Rosano, Petar Seferović, Razvan I Radu, Gianluigi Savarese, Beth Davison, Alexandru Ababei, Marija Polovina, Anika Naidu, Òscar Miró, Luca Monzo, Alberto Palazzuoli, Teodora Radu, Lars H Lund, Tuvia Ben Gal, Maurizio Volterrani, Ovidiu Chioncel, Gad Cotter, Mandeep R Mehra, Javed Butler, Andrew Js Coats, Vlad Iliescu","doi":"10.15420/cfr.2025.51","DOIUrl":"10.15420/cfr.2025.51","url":null,"abstract":"<p><p>Acute heart failure (AHF) is a systemic condition characterised by multiorgan involvement that varies from subclinical to overt organ failure. The liver is particularly vulnerable due to its dual blood supply and sensitivity to haemodynamic and inflammatory disturbances. Abnormal liver function tests are highly prevalent in patients with AHF, reflecting major mechanisms: passive hepatic venous congestion from elevated central venous pressure, hepatocellular ischaemia from low cardiac output, systemic inflammation and poor metabolic status associated with cachexia. In patients with AHF, liver function tests at admission, during hospitalisation and at discharge are independently associated with rehospitalisation, cardiovascular and all-cause mortality. Persistent abnormalities after hospitalisation often reflect incomplete decongestion or irreversible structural liver changes. Therapeutic strategies focus on decongestion, optimisation of cardiac output and medication adjustments to avoid hepatotoxicity. Despite significant advances in understanding cardio-hepatic interactions, major gaps remain, including the lack of standardised definitions, limited mechanistic studies and the underrepresentation of patients with heart failure with preserved ejection fraction in contemporary research. Future research should explore targeted therapies to improve cardiohepatic interactions and patient outcomes.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e17"},"PeriodicalIF":12.2,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13392301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148580408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Heart Failure in Heart Failure with Preserved Ejection Fraction: A State-of-the-art Review from an International Expert Group.","authors":"Razvan I Radu, Beth Davison, Sean P Collins, Alexandre Mebazaa, Gianluigi Savarese, Òscar Miró, Priyanka Morishetty, Oliviana Geavlete, Maurizio Volterrani, Chris Edwards, Marianna Adamo, Lars H Lund, Koji Takagi, Giuseppe Mc Rosano, Marco Metra, Mandeep R Mehra, Alberto Palazzuoli, Marija Polovina, Andrew P Ambrosy, Anika S Naidu, Stefan D Anker, Javed Butler, Ovidiu Chioncel, Andrew Js Coats, Gad Cotter","doi":"10.15420/cfr.2025.56","DOIUrl":"10.15420/cfr.2025.56","url":null,"abstract":"<p><p>Acute heart failure with preserved ejection fraction (acute heart failure-heart failure with preserved ejection fraction) is increasingly prevalent, resulting from the interaction between a dysfunctional ventricle, the patient's comorbidity burden and acute triggers. Patients are typically older, commonly female and have cardiometabolic, renal, arrhythmic, ischaemic and inflammatory comorbidities that produce vulnerability to decompensation. Acute episodes manifest with pulmonary and/or systemic congestion, from abrupt rises in left-sided filling pressures due to cardiac and arterial stiffness driven by neurohormonal activation and inflammation. Congestion and elevated blood pressure are common, but clinical presentation is more heterogeneous, reflecting the haemodynamic abnormalities, severity of triggers and comorbidity load. Diagnosis relies on integrating clinical context, echocardiography, adjusted thresholds of natriuretic peptides, and invasive and/or stress haemodynamics when diagnosis is uncertain. Management requires individualised decongestion, alongside treatment of precipitants. Early initiation of disease-modifying therapies after haemodynamic stability, including sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists, improves outcomes. Acute heart failure-heart failure with preserved ejection fraction follows a relapsing-remitting trajectory, underscoring the importance of comorbidity management, structured follow-up and preventive strategies.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e16"},"PeriodicalIF":12.2,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13389318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148563129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mineralocorticoid Receptor Antagonist Use in Contemporary Heart Failure Care.","authors":"Jolie Bruno, Alexandre Mebazaa, Lídia Zytynski Moura, Jelena Čelutkienė, Andrew Sindone, Giuseppe Rosano","doi":"10.15420/cfr.2025.57","DOIUrl":"10.15420/cfr.2025.57","url":null,"abstract":"<p><p>Heart failure (HF) continues to challenge clinicians worldwide, not only because of its high morbidity and mortality, but also due to the persistent difficulty in translating therapeutic advances into routine care. Despite the availability of effective treatments, data show striking gaps in the optimal use of guideline-directed medical therapy. Among the four pillars of guideline-directed medical therapy, mineralocorticoid receptor antagonists (MRAs) remain the least prescribed. This underuse is concerning considering the evidence demonstrating consistent benefits of MRAs across different HF phenotypes. In this review, we revisit the role of MRAs across the spectrum of HF. We summarise the supporting evidence, discuss their mechanisms of action and provide practical guidance on patient eligibility and initiation strategies. In addition, we address common barriers that often limit their use. By combining mechanistic insights, trial evidence and pragmatic recommendations, this review aims to facilitate broader and earlier use of MRAs, thereby helping to close a major gap in the implementation of evidence-based HF care.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e15"},"PeriodicalIF":12.2,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13294565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148346538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valvular Heart Disease in Heart Failure with Preserved Ejection Fraction.","authors":"Athena Adeli, Revathy Sampath-Kumar, Anne Wang, Aristomenis Manouras, Gianluigi Savarese, Rebecca T Hahn, Lars H Lund, Bahira Shahim","doi":"10.15420/cfr.2025.13","DOIUrl":"10.15420/cfr.2025.13","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is associated with reduced functional capacity and quality of life, as well as with high rates of heart failure hospitalisation and mortality. Valvular heart disease (VHD) is frequently encountered in patients with HFpEF, and both conditions share common risk factors, such as age, hypertension, diabetes and coronary artery disease, which may contribute to their shared pathogenesis and progression. With recent advances in percutaneous therapies for VHD and an improved understanding of HFpEF, there is a growing interest in the relationship between VHD and HFpEF. In this review, we provide an overview of the pathophysiology, epidemiology and management strategies of tricuspid regurgitation, mitral regurgitation, aortic stenosis and aortic regurgitation in the setting of HFpEF.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e14"},"PeriodicalIF":12.2,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13284787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148309319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}